F-1/A: Clearmind Medicine Registers 12.5M Shares for Resale

Clearmind Medicine Inc. files an amended F-1 registration statement to register 12,545,230 common shares for resale by selling shareholders, stemming from warrant adjustments and recent capital raises.

Summary

• Clearmind Medicine Inc. is a clinical pharmaceutical company focused on developing novel psychedelic medicines, primarily MEAI, for Alcohol Use Disorder (AUD), weight loss, metabolic disorders, and as an alcohol substitute.
• The company filed an F-1/A to register 12,545,230 common shares for resale by selling shareholders, which are issuable upon the exercise of January 2024 PIPE Warrants, adjusted due to the issuance of convertible promissory notes in September 2025.
• The company will not receive proceeds from the sale of shares by selling shareholders, but may receive proceeds from warrant exercises if not on a cashless basis, estimated at approximately $1.16 million if all exercised for cash.
• The company is currently non-compliant with Nasdaq's Minimum Stockholders Equity Rule, reporting $1,065,668 in stockholders' equity as of July 31, 2025, against a required $2,500,000.
• Recent capital raises in November and December 2025, totaling approximately $7.244 million, and warrant exercises for $183,000 are expected to help regain Nasdaq compliance.
• The CMND-100 (MEAI) Phase I/IIa clinical trial for AUD is ongoing in Israel and the United States (Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, Hadassah Medical Center).
• Pre-clinical studies for MEAI indicate potential for treating obesity, metabolic syndrome, and cocaine addiction, with a favorable safety profile observed in the first human cohort (20mg dose) and DSMB approval to continue and increase the dose to 40mg.
• The company has incurred significant operating losses since inception, with an accumulated deficit of $27,191,882 as of July 31, 2025.
• The company holds an extensive intellectual property portfolio comprising 19 utility patent families, including 30 granted patents and 53 pending applications.

Sentiment

Score: 4

Explanation: While the company demonstrates promising scientific advancements in psychedelic medicine and has secured recent financing, the persistent operating losses, explicit 'going concern' warning, and current Nasdaq non-compliance indicate significant financial instability and high operational risk. The positive clinical and IP developments are overshadowed by the immediate financial challenges and the long, uncertain path to commercialization.

Positives

• The independent Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the Phase I/IIa clinical trial for CMND-100 following a positive interim safety review of the 20mg dose, recommending an increase to 40mg.
• Pre-clinical research studies for MEAI demonstrated anti-obesity effects (reduced diet-induced obesity and adiposity, improved glycemic control, reduced hepatic steatosis, increased energy expenditure) and potential efficacy in treating cocaine addiction without interrupting natural reward processes.
• The company possesses a robust intellectual property portfolio with 19 patent families, including 30 granted patents and 53 pending applications, covering various psychedelic compounds and their uses.
• Successful capital raises in November and December 2025, totaling approximately $7.244 million, along with $183,000 from warrant exercises, are expected to improve the company's financial position and aid in regaining Nasdaq compliance.
• MEAI is a non-hallucinogenic neuroplastogen, which could offer a unique and potentially less controversial treatment approach for mental health disorders.
• Strategic collaborations with academic institutions like the Hebrew University of Jerusalem and Bar Ilan University are advancing research programs.

Negatives

• The company has incurred substantial operating losses since its inception, with an accumulated deficit reaching $27,191,882 as of July 31, 2025.
• The financial statements include an explanatory paragraph highlighting substantial doubt about the company's ability to continue as a going concern.
• The company is currently non-compliant with Nasdaq Listing Rule 5550(b)(1), requiring a minimum of $2,500,000 in stockholders' equity, having reported only $1,065,668 as of July 31, 2025.
• No revenue has been generated from product sales to date, and significant losses are anticipated for the foreseeable future.
• The Israeli study site (IMCA) for the CM-CMND-001 clinical trial was concluded in July 2025 due to financial considerations.
• The registration for resale of 12,545,230 common shares by selling shareholders could lead to a substantial increase in shares available in the public market, potentially depressing the market price of the common shares.

Risks

• The company has incurred losses since inception and anticipates significant losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, which could hinder new financing.
• Substantial additional funding will be required, which may not be available on acceptable terms or at all, potentially leading to curtailment or discontinuation of product development.
• Product candidates are in preclinical/early clinical development, a lengthy and expensive process with uncertain outcomes and potential for substantial delays, with no assurance of regulatory approval.
• Product candidates contain psychedelic substances, which may be subject to controlled substance laws and regulations, and public controversy, potentially affecting business operations and financial condition.
• The results of early-stage clinical trials and preclinical studies may not be predictive of future results, and initial data may not be indicative of results obtained in later-stage trials.
• Research and development of drugs targeting the Central Nervous System (CNS) is particularly difficult, making it hard to predict drug effects on patients.
• Difficulties in enrolling patients in future clinical trials could delay or adversely affect clinical development activities.
• Use of product candidates could be associated with side effects, adverse events, or other safety risks, potentially delaying or halting clinical development or preventing regulatory approval.
• Even if approved, product candidates may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors, limiting commercial success.
• Inability to obtain regulatory approval in one or more jurisdictions for product candidates would substantially harm the business.
• Interim, top-line, and preliminary data from clinical trials may change as more patient data become available or additional analyses are conducted.
• Manufacturing problems for complex product candidates could result in delays in development or commercialization programs.
• The company may not be able to take advantage of expedited development or regulatory review processes (e.g., breakthrough therapy, fast track designation).
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense and potential penalties for non-compliance.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties could hinder commercialization efforts.
• Uncertain third-party payor coverage and reimbursement status, or unfavorable pricing regulations, could harm the business.
• Failure to comply with healthcare laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA) could lead to substantial penalties.
• The company may become subject to U.S. federal and state forfeiture laws due to involvement with scheduled drugs.
• Significant competition in the pharmaceutical industry, with competitors potentially achieving regulatory approval first or developing superior therapies.
• Market opportunities for product candidates may be smaller than believed, adversely affecting revenue and growth.
• Reliance on third parties for collaborations, clinical trials, and manufacturing increases risks of unsatisfactory performance or supply disruptions.
• Inability to obtain and maintain effective patent rights or protect trade secrets/know-how could impair competitive position.
• Insufficient patent lifespan to effectively protect products and business.
• Changes in patent laws or interpretations could diminish the value of patents.
• Difficulties in protecting intellectual property rights globally.
• Difficulties in managing organizational growth due to expansion.
• Prioritization of certain product candidates over others due to limited resources may lead to missed opportunities.
• Failure to identify, discover, or license additional product candidates.
• Restrictive European data collection regulations (GDPR) and Brexit may adversely impact operations in Europe.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Misconduct by employees or independent contractors, including noncompliance with regulatory standards or fraud.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Certain directors and officers may have competing interests due to affiliations with other entities.
• Conditions in Israel, including ongoing military conflicts and geopolitical instability, may materially and adversely affect operations, and insurance may not cover associated losses.
• Difficulty enforcing U.S. judgments against the company or its non-U.S. officers and directors in Israel or Canada.
• Significant increased costs and management time required for operating as a public company in the United States.
• Inability to attract and retain highly skilled managerial, scientific, technical, and marketing personnel.
• Security breaches, including cybersecurity incidents, could adversely affect business and operations.
• Sales of a significant number of common shares by selling shareholders or significant short sales could depress the market price.
• If securities or industry analysts cease publishing research or publish negative reports, the share price and trading volume could decline.

Future Outlook

The company anticipates increased expenses and operating losses for the foreseeable future as it continues the clinical development of MEAI for Alcohol Use Disorder (AUD) and obesity/metabolic disorder. Future revenue and profitability are dependent on the successful development, regulatory approvals, manufacturing, marketing, and commercialization of product candidates. The company expects to require substantial additional financing, which may not always be available on acceptable terms. Management believes their MEAI drug candidate has the potential to address significant unmet needs in mental health disorders, including AUD, obesity, and cocaine addiction, and that the world is transitioning towards greater acceptance of psychedelic use in medicine.

Management Comments

• "Our goal is to develop and provide new type of treatments for mental health disorders, including AUD, binge drinking and eating disorders, where there is significant unmet need and lack of innovation."
• "We see neuroplastogens based therapies, which previously may have been overlooked or underused, as the future of treatment for a variety of indications."
• "We believe that our solution for AUD can help solve one of the worlds biggest health problems, which costs the United States alone roughly $250 billion each year."
• "Apart from potentially changing peoples lives, we believe that our treatment could potentially reduce the amount currently being spent on the consequences of AUD in the United States, Europe, India, China and other countries around the world."
• "We also believe that our treatment may address binge drinking."
• "On the consumer side, we are developing an alcohol substitute which may offer a solution that adults can enjoy without the extensive damage that comes with alcohol."
• "Although MEAI remains in development and is not cleared or approved by the FDA or similar foreign regulatory bodies, we believe that our drug candidate has the potential to change the lives of millions who struggle to drink in moderation."
• "We believe that MEAI holds the potential to break the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to sensible behavior."
• "We believe that psychedelic solutions such as our drug candidate may hold the key to providing much needed solutions to various disorders and conditions, including, but not limited to, obesity, weight loss and metabolic disorder, depression, anxiety, and cocaine addiction."
• "We believe that the world is transitioning to become a place that is more accepting of psychedelic use, and a revolution in medicine is on the horizon."
• "As we continue to grow our Company, our goal is to continue to invest, develop and produce solutions to help patients that suffer from mental health disorders. We strive to get millions of people out of the cycle of addiction, anxiety, and depression. Not only do we aim to uplift those that are struggling but also their families, communities, and societies."
• "Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Companys liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company."

Industry Context

The company operates within the rapidly evolving psychedelic medicine industry, which is gaining increasing scientific and regulatory validation for treating mental health disorders. This sector is experiencing a 'revolution in medicine' as novel approaches challenge traditional therapies. Clearmind Medicine strategically focuses on Alcohol Use Disorder (AUD), obesity, metabolic disorders, and cocaine addiction, identifying these as areas underserved by the broader psychedelic industry. The FDA's approval of Esketamine for treatment-resistant depression and breakthrough therapy designation for psilocybin, alongside MAPS's MDMA application for PTSD, underscore a growing regulatory acceptance of psychedelic-assisted therapies. The company faces intense competition from established pharmaceutical, biotechnology, and specialty pharmaceutical firms, as well as other emerging psychedelic companies like Awakn Life Sciences, B.More Inc., and Journey Colab Corp.

Comparison to Industry Standards

• Current FDA-approved medications for AUD (disulfiram, naltrexone, acamprosate) have limitations, including high relapse rates and inconvenient treatment regimens, which Clearmind Medicine aims to overcome with its MEAI treatment.
• Pre-clinical studies suggest MEAI and MDMA have similar mechanisms of action, but MEAI is believed to have less abuse liability due to releasing less dopamine and more serotonin, potentially offering a more appealing alternative for certain pharmaceutical treatments.
• The company's focus on CNS disorders places it in a challenging R&D area, historically marked by higher failure rates compared to other drug discovery fields, as seen with Pharmos, Roche, Allegran's NMDA, and Merck.
• The broader psychedelic industry is seeing increased regulatory acceptance, with Esketamine's FDA approval for TRD and psilocybin's breakthrough therapy designation, indicating a favorable environment for novel psychedelic treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• **Cooperation Agreement with SciSparc Ltd.**: Entered into on March 7, 2022, to explore scientific and commercial potential for pharmaceutical solutions. Dr. Adi Zuloff-Shani (CEO), Amitay Weiss (Chairman), and Oz Adler (Director) hold positions at SciSparc. The collaboration has resulted in nine patent filings, with a potential 50%-50% joint venture for commercial cooperation.
• **Research Agreement with Hebrew University of Jerusalem**: Entered into in June 2023 as part of the SciSparc collaboration to evaluate combination treatment for obesity and metabolic syndrome.
• **Office Space Lease with SciSparc**: The company shares office space with SciSparc. A lease agreement was entered into on June 13, 2024, for office space in Tel Aviv, Israel, with a rental period from April 1, 2024, to March 31, 2026, at ILS 12,500 per month (approximately $3,400). A previous lease with SciSparc was terminated on March 31, 2024, incurring approximately $13,000 in early termination fees.
• **Compensation to Key Management Personnel**: Includes consulting fees and share-based compensation for officers and directors, as detailed in the compensation table for the years ended October 31, 2024, and 2025 (nine months ended July 31, 2025).

Stakeholder Impact

• **Shareholders**: Face potential dilution from the resale of 12,545,230 common shares by selling shareholders and future equity issuances. The Nasdaq non-compliance and 'going concern' warning pose significant risks to share price and market liquidity. Potential for adverse tax consequences if the company is classified as a Passive Foreign Investment Company (PFIC).
• **Employees**: The company's future success is dependent on its ability to attract, retain, and motivate highly qualified management, clinical, and scientific personnel. Misconduct by employees or contractors could lead to regulatory sanctions and reputational damage.
• **Patients**: Potential for new and improved treatments for Alcohol Use Disorder, obesity, metabolic disorders, and cocaine addiction if the company's product candidates successfully complete clinical trials and receive regulatory approval. However, there are inherent risks related to drug development, including side effects, efficacy, and regulatory delays.
• **Creditors**: The 'going concern' uncertainty and accumulated deficit raise concerns about the company's ability to meet its financial obligations, potentially impacting its creditworthiness.
• **Regulatory Bodies**: The company is subject to extensive and evolving regulations from the FDA, EMA, DEA, and other authorities. Non-compliance could result in fines, injunctions, withdrawal of approvals, and other significant penalties.

Next Steps

• Conduct additional clinical trials for CMND-100 after the completion of Phase I/IIa studies, contingent on securing further financing.
• Submit a plan to Nasdaq by December 18, 2025, to regain compliance with the Minimum Stockholders Equity Rule.
• Continue to invest in, develop, and produce solutions for mental health disorders.
• Seek regulatory approval for MEAI through the FDA's 505(b)(1) regulatory pathway.
• Decide whether to file non-provisional patent applications for provisional patent families before their respective lapse dates.
• Potentially enter into a joint venture with SciSparc for commercial cooperation if feasibility studies prove successful.

Key Dates

Recommendation

Clearmind Medicine is engaged in high-potential, yet high-risk, clinical development of psychedelic compounds for significant unmet medical needs. The positive interim safety data for CMND-100 and promising preclinical results for other indications are encouraging. However, the company's substantial accumulated losses, explicit 'going concern' warning, and current non-compliance with Nasdaq's minimum stockholders' equity rule present considerable financial instability. While recent capital raises provide some short-term liquidity and address Nasdaq compliance, the long and uncertain path to regulatory approval and commercialization, coupled with potential dilution from the large volume of shares registered for resale, warrants a 'Hold' recommendation. Investors should closely monitor clinical trial progress, financial health, and successful resolution of Nasdaq listing issues before considering further investment.

Keywords

Psychedelic medicine, Alcohol Use Disorder, MEAI, Clinical trials, Biotechnology, Mental health, Obesity, Metabolic disorders, Cocaine addiction, Nasdaq listing, SEC filing, Drug development, Neuroplastogen, CMND-100, Warrants, Capital raise